These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 33465114)

  • 21. The clinicopathological and prognostic significances of IGF-1R and Livin expression in patients with colorectal cancer.
    Zhang Z; Zhang Y; Lao S; Qiu J; Pan Z; Feng X
    BMC Cancer; 2022 Aug; 22(1):855. PubMed ID: 35931997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
    Schulze-Bergkamen H; Ehrenberg R; Hickmann L; Vick B; Urbanik T; Schimanski CC; Berger MR; Schad A; Weber A; Heeger S; Galle PR; Moehler M
    World J Gastroenterol; 2008 Jun; 14(24):3829-40. PubMed ID: 18609706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
    Le Roy B; Tixier L; Pereira B; Sauvanet P; Buc E; Pétorin C; Déchelotte P; Pezet D; Balayssac D
    PLoS One; 2016; 11(2):e0148739. PubMed ID: 26859833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional mismatch repair and inactive p53 drive sensitization of colorectal cancer cells to irinotecan via the IAP antagonist BV6.
    Tomicic MT; Steigerwald C; Rasenberger B; Brozovic A; Christmann M
    Arch Toxicol; 2019 Aug; 93(8):2265-2277. PubMed ID: 31289894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin.
    Nagourney RA; Evans S; Tran PH; Nagourney AJ; Sugarbaker PH
    Eur J Surg Oncol; 2021 Apr; 47(4):738-742. PubMed ID: 33004272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in defective mismatch repair colon cancer.
    Sargent DJ
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):639-41. PubMed ID: 18827786
    [No Abstract]   [Full Text] [Related]  

  • 29. XRCC2-Deficient Cells are Highly Sensitive to 5-Fluorouracil in Colorectal Cancer.
    Zhang YZ; An JH; Liu YX; Wu XC; Han SS; Ren XQ; Qin CJ
    Cell Physiol Biochem; 2017; 43(3):1207-1219. PubMed ID: 28977800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents.
    Kucherlapati MH; Lee K; Nguyen AA; Clark AB; Hou H; Rosulek A; Li H; Yang K; Fan K; Lipkin M; Bronson RT; Jelicks L; Kunkel TA; Kucherlapati R; Edelmann W
    Gastroenterology; 2010 Mar; 138(3):993-1002.e1. PubMed ID: 19931261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
    Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
    J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer.
    Paradiso A; Simone G; Lena MD; Leone B; Vallejo C; Lacava J; Dellapasqua S; Daidone MG; Costa A
    Br J Cancer; 2001 Mar; 84(5):651-8. PubMed ID: 11237386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Livin and Bcl-2 expression in high-grade osteosarcoma.
    Nedelcu T; Kubista B; Koller A; Sulzbacher I; Mosberger I; Arrich F; Trieb K; Kotz R; Toma CD
    J Cancer Res Clin Oncol; 2008 Feb; 134(2):237-44. PubMed ID: 17632732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
    Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
    BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer.
    Sreekumar R; Al-Saihati H; Emaduddin M; Moutasim K; Mellone M; Patel A; Kilic S; Cetin M; Erdemir S; Navio MS; Lopez MA; Curtis N; Yagci T; Primrose JN; Price BD; Berx G; Thomas GJ; Tulchinsky E; Mirnezami A; Sayan AE
    Mol Oncol; 2021 Aug; 15(8):2065-2083. PubMed ID: 33931939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-
    Schelhaas S; Wachsmuth L; Hermann S; Rieder N; Heller A; Heinzmann K; Honess DJ; Smith DM; Fricke IB; Just N; Doblas S; Sinkus R; Döring C; Schäfers KP; Griffiths JR; Faber C; Schneider R; Aboagye EO; Jacobs AH
    J Nucl Med; 2018 Jul; 59(7):1063-1069. PubMed ID: 29476002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
    Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis.
    Guo J; Yu Z; Das M; Huang L
    ACS Nano; 2020 Apr; 14(4):5075-5089. PubMed ID: 32283007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic and Predictive Role of Excision Repair Cross-complementation Group 1 and Thymidylate Synthase in Colorectal Carcinoma Patients Received FOLFOX Chemotherapy: An Immunohistochemical Study.
    Badary DM; Elkabsh MM; Mady HH; Gabr A; Kroosh SS
    Appl Immunohistochem Mol Morphol; 2020; 28(10):741-747. PubMed ID: 32118594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.